Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Items 201–300 of 1,002
Harris, S. T., Blumentals, W. A., & Miller, P. D. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253717 · Cited by 141
Strategies for the prevention and treatment of osteoporosis during early postmenopause
Delaney, M. F. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.08.049 · Cited by 141
One year outcomes and costs following a vertebral fracture
Lindsay, R., Burge, R. T., & Strauss, D. M. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1646-x · Cited by 140
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1743 · Cited by 139
RetractedLong-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years
Reginster, J., Bruyère, O., Sawicki, A., Roces-Varela, A., Fardellone, P., Roberts, A., & Devogelaer, J.-P. (2009) · Bone · doi:10.1016/j.bone.2009.08.004 · Cited by 139
Self-citationPostmenopausal osteoporosis: Assessment and management
Rizzoli, R. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.09.005 · Cited by 139
Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis
Strampel, W., Emkey, R. D., & Civitelli, R. (2007) · Drug Safety · doi:10.2165/00002018-200730090-00003 · Cited by 139
Mudano, A. S., Bian, J., Cope, J. U., Curtis, J. R., Gross, T. P., Allison, J. J., Kim, Y., Briggs, D. T., Melton, M. E., Xi, J., et al. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0745-5 · Cited by 139
Bone safety of long-term bisphosphonate treatment
Rodan, G. A., Reszka, A. A., Golub, E. E., & Rizzoli, R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004475 · Cited by 139
Landfeldt, E., Ström, O., Robbins, S., & Borgström, F. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1549-6 · Cited by 137
Important Determinants of Bone Strength: Beyond Bone Mineral Density
Friedman, A. (2006) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000208612.33819.8c · Cited by 137
Cosman, F., Krege, J. H., Looker, A. C., Schousboe, J. T., Fan, B., Sarafrazi, N., Shepherd, J., Krohn, K., Steiger, P., Wilson, K. E., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3948-9 · Cited by 136
Harris, S. T., Eriksen, E. F., Davidson, M., Ettinger, M. P., Moffett Jr., A. H., Baylink, D. J., Crusan, C. E., & Chines, A. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7505 · Cited by 134
Boonen, S., Black, D. M., Colón‐Emeric, C. S., Eastell, R., Magaziner, J. S., Eriksen, E. F., Mesenbrink, P., Haentjens, P., & Lyles, K. W. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02673.x · Cited by 134
Self-citationPharmacological treatment of osteoporosis in the oldest old
Vandenbroucke, A.-M., Luyten, F., Flamaing, J., & Gielen, E. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s131023 · Cited by 118
Komatsubara, S., Mori, S., Mashiba, T., Li, J., Nonaka, K., Kaji, Y., Akiyama, T., Miyamoto, K., Cao, Y., Kawanishi, J., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040126 · Cited by 133
Is bone mineral density predictive of fracture risk reduction?
Cefalu, C. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003062 · Cited by 132
Lorentzon, M., Branco, J., Brandi, M. L., Bruyère, O., Chapurlat, R. D., Cooper, C. C., Cortet, B., Díez‐Pérez, A., Ferrari, S., Gáspárik, A. I., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01063-9 · Cited by 132
Self-citationInteraction Between Bone and Muscle in Older Persons with Mobility Limitations
Ferrucci, L., Baroni, M., Ranchelli, A., Lauretani, F., Maggio, M., Mecocci, P., & Ruggiero, C. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660690 · Cited by 131
Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study
Adami, S., Isaia, G., Luisetto, G., Minisola, S., SINIGAGLIA, L., Gentilella, R., Agnusdei, D., Iori, N., & Nuti, R. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060715 · Cited by 131
Montagnani, A., Gonnelli, S., Cepollaro, C., Pacini, S., Campagna, M. S., Franci, M. B., Lucani, B., & Gennari, C. (2003) · Bone · doi:10.1016/s8756-3282(03)00034-6 · Cited by 131
Brixen, K. T., Christensen, B., Ejersted, C., & Langdahl, B. L. (2004) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2004.pto940602.x · Cited by 131
Osteoporosis in Men and Women: A Story About Bone Mineral Density Thresholds and Hip Fracture Risk
Laet, C. E. D. H. D., van der Klift, M., Hofman, A., & Pols, H. A. P. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.12.2231 · Cited by 131
A comprehensive review of treatments for postmenopausal osteoporosis
Häuselmann, H. J., & Rizzoli, R. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1301-3 · Cited by 131
Cosman, F., Cauley, J. A., Eastell, R., Boonen, S., Palermo, L., Reid, I. R., Cummings, S. R., & Black, D. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1971 · Cited by 129
Self-citationPfeifer, M. A., Kohlwey, L., Begerow, B., & Minne, H. W. (2011) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e31821f6df3 · Cited by 129
Self-citationDelmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 129
Bisphosphonates and Atrial Fibrillation: Systematic Review and Meta-Analysis
Loke, Y. K., Jeevanantham, V., & Singh, S. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00004 · Cited by 128
Underreporting of Vertebral Fractures on Routine Chest Radiography
Kim, N., Rowe, B. H., Raymond, G., Jen, H., Colman, I., Jackson, S. A., Siminoski, K. G., Chahal, A. M., Folk, D., & Majumdar, S. R. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.182.2.1820297 · Cited by 127
Bisphosphonates in osteoporosis
Fleisch, H. A. (2003) · European Spine Journal · doi:10.1007/s00586-003-0622-z · Cited by 127
Boonen, S., Ferrari, S., Miller, P. D., Eriksen, E. F., Sambrook, P. N., Compston, J., Reid, I. R., Vanderschueren, D., & Cosman, F. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1570 · Cited by 114
A multicenter survey on profile of care for hip fracture: predictors of mortality and disability
For the Hip Fracture Study Group, Maggi, S., Siviero, P., Wetle, T. T., Besdine, R. W., Saugo, M., & Crepaldi, G. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0936-8 · Cited by 126
Bone Disease in CKD: A Focus on Osteoporosis Diagnosis and Management
Miller, P. D. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.12.018 · Cited by 125
Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis
Reginster, J. (2010) · Drugs · doi:10.2165/11587570-000000000-00000 · Cited by 125
Self-citationAdherence, patient preference and dosing frequency: Understanding the relationship
Reginster, J., Rabenda, V., & Neuprez, A. (2006) · Bone · doi:10.1016/j.bone.2006.01.150 · Cited by 125
Self-citationBarr, J. D., Jensen, M. E., Hirsch, J. A., McGraw, J. K., Barr, R. M., Brook, A., Meyers, P. M., Munk, P. L., Murphy, K. J., OʼToole, J. E., et al. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2013.10.001 · Cited by 124
Bisphosphonates for the treatment of osteoporosis: insights for clinicians
Lewiecki, E. M. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310374783 · Cited by 122
An Approach to Identifying Osteopenic Women at Increased Short-term Risk of Fracture
Miller, P. D., Barlas, S., Brenneman, S. K., Abbott, T. A., Chen, Y.-T., Barrett-Connor, E. L., & Siris, E. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1113 · Cited by 122
Seibel, M. J., Naganathan, V., Barton, I. P., & Grauer, A. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301231 · Cited by 121
Delmas, P. D., Munoz, F., Black, D. M., Cosman, F., Boonen, S., Watts, N. B., Kendler, D., Eriksen, E. F., Mesenbrink, P. G., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090310 · Cited by 120
Self-citationKomatsubara, S., Mori, S., Mashiba, T., Ito, M., Li, J., Kaji, Y., Akiyama, T., Miyamoto, K., Cao, Y., Kawanishi, J., et al. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.3.512 · Cited by 119
Geusens, P., Marin, F., Kendler, D. L., Russo, L. A., Zerbini, C. A., Minisola, S., Body, J. J., Lespessailles, E., Greenspan, S. L., Bagur, A., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3384 · Cited by 116
Delmas, P., Li, Z., & Cooper, C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301228 · Cited by 118
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
Russell, R. G. G. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s8054 · Cited by 118
Saito, T., Sterbenz, J. M., Malay, S., Zhong, L., MacEachern, M., & Chung, K. C. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4175-0 · Cited by 118
Raloxifene enhances vertebral mechanical properties independent of bone density
Allen, M. R., Iwata, K., Sato, M., & Burr, D. B. (2006) · Bone · doi:10.1016/j.bone.2006.05.007 · Cited by 118
Treatment of osteoporosis in men
Kaufman, J., Reginster, J.-Y., Boonen, S., Brandi, M. L., Cooper, C. C., Dere, W. H., Devogelaer, J.-P., Díez‐Pérez, A., Kanis, J. А., McCloskey, E. V., et al. (2012) · Bone · doi:10.1016/j.bone.2012.11.018 · Cited by 117
Self-citationVertebroplasty and kyphoplasty: a comparative review of efficacy and adverse events
McCall, T. D., Cole, C. D., & Dailey, A. T. (2008) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-007-9013-0 · Cited by 117
Renal safety in patients treated with bisphosphonates for osteoporosis: A review
Miller, P. D., Jamal, S. A., Evenepoel, P., Eastell, R., & Boonen, S. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2058 · Cited by 116
Self-citationBody, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J.-Y. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1223-4 · Cited by 116
Self-citationUses and limitations of bone mineral density measurements in the management of osteoporosis.
Small, R. E. (2005) · PubMed · Cited by 116
Jansen, J. P., Bergman, G., Huels, J., & Olson, M. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.06.001 · Cited by 113
Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden
Kanis, J. А., Johnell, O., Odén, A., Borgström, F., Johansson, H., Laet, C. E. D. H. D., & Jönsson, B. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1623-4 · Cited by 113
Osteoporosis in Older Persons: Old and New Players
Zanker, J., & Duque, G. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15716 · Cited by 112
Effect of Alendronate on the Age-Specific Incidence of Symptomatic Osteoporotic Fractures
Hochberg, M. C., Thompson, D. E., Black, D. M., Quandt, S. A., Cauley, J. A., Geusens, P., Ross, P. D., & Baran, D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050104 · Cited by 112
The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis
Byun, J.-H., Jang, S., Lee, S., Park, S., Yoon, H. K., Yoon, B., & Ha, Y. (2017) · Journal of Bone Metabolism · doi:10.11005/jbm.2017.24.1.37 · Cited by 111
Bisphosphonate treatment of osteoporosis
Watts, N. B. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00069-1 · Cited by 111
Curtis, J. R., Westfall, A. O., Cheng, H. M., Lyles, K. W., Saag, K. G., & Delzell, E. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080418 · Cited by 111
Cooper, M. S., Palmer, A. J., & Seibel, M. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1802-z · Cited by 111
Macías, J. G., Gay, N. G., Alonso, C. G., Barquero, L. M. D. R., Torres, M. M., Delgado‐Rodríguez, M., Pérez-Edo, L., López, J. B. D., Gimeno, E. J., & Carranza, F. H. (2008) · Revista Clínica Española · doi:10.1016/s0014-2565(08)71780-6 · Cited by 111
Rizzoli, R., Body, J., DeCensi, A., Reginster, J., Piscitelli, P., & Brandi, M. L. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1870-0 · Cited by 111
Self-citationPreventing osteoporosis: outcomes of the Australian Fracture Prevention Summit
Sambrook, P. N., Seeman, E., Phillips, S. R., & Ebeling, P. R. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04475.x · Cited by 111
Efficacy and safety of ibandronate given by intravenous injection once every 3 months
Adámi, S., Felsenberg, D., Christiansen, C., Robinson, J., Lorenc, R. S., Mahoney, P., Coutant, K., Schimmer, R. C., & Delmas, P. D. (2004) · Bone · doi:10.1016/j.bone.2004.01.007 · Cited by 111
The Treatment Gap in Osteoporosis
Ayub, N., Faraj, M., Ghatan, S., Reijers, J. A. A., Napoli, N., & Oei, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10133002 · Cited by 98
Marcus, R. (2002) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1053/beog.2002.0284 · Cited by 110
Boonen, S., Nijs, J., Borghs, H., Peeters, H., Vanderschueren, D., & Luyten, F. P. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1660-z · Cited by 110
Drug Insight: bisphosphonates for postmenopausal osteoporosis
Chapurlat, R. D., & Delmas, P. D. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0121 · Cited by 109
Efficacy and safety of monthly ibandronate in men with low bone density
ORWOLL, E. S., Binkley, N., Lewiecki, E. M., Gruntmanis, U., Fries, M. A., & Dašić, G. (2010) · Bone · doi:10.1016/j.bone.2009.12.034 · Cited by 109
Kanis, J. A., Barton, I. P., & Johnell, O. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1698-y · Cited by 108
Canadian Consensus Conference on Menopause, 2006 Update
Bélisle, S., Blake, J. M., Basson, R. J., Desindes, S., Graves, G. R., Grigoriadis, S., Johnston, S. L., Lalonde, A. B., Mills, C., Nash, L., et al. (2006) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32086-2 · Cited by 108
Cummings, S. R., Lui, L., Eastell, R., & Allen, I. E. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2779 · Cited by 107
Self-citationUpper Gastrointestinal Tract Safety of Risedronate: A Pooled Analysis of 9 Clinical Trials
Taggart, H. M., Bolognese, M. A., Lindsay, R., Ettinger, M. P., Mulder, H., Josse, R. G., Roberts, A., Zippel, H., Adami, S., Ernst, T. F., et al. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.3.262 · Cited by 107
Update of current therapeutic options for the treatment of postmenopausal osteoporosis
Epstein, S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.02.007 · Cited by 106
Postmenopausal Osteoporosis: A Literature Review
Bhatnagar, A., & Kekatpure, A. L. (2022) · Cureus · doi:10.7759/cureus.29367 · Cited by 105
Bonnick, S. L. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80063-3 · Cited by 105
Lack of Diagnosis and Treatment of Osteoporosis in Men and Women After Hip Fracture
Follin, S. L., Black, J. N., & McDermott, M. T. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.2.190.32090 · Cited by 105
Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Candelas, G., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.09.004 · Cited by 104
Hopkins, R. B., Goeree, R. A., Pullenayegum, E., Adachi, J. D., Παπαϊωάννου, Α., Xie, F., & Thabane, L. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-209 · Cited by 104
Management of osteoporosis of the oldest old
Rizzoli, R., Branco, J., Brandi, M. L., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C. C., Díez‐Pérez, A., Duder, J., Fielding, R. A., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2755-9 · Cited by 104
Self-citationNonresponders to Osteoporosis Therapy
Lewiecki, E. M. (2003) · Journal of Clinical Densitometry · doi:10.1385/jcd:6:4:307 · Cited by 104
Grizon, F., Aguado, E., Huré, G., Baslé, M. F., & Chappard, D. (2002) · Journal of Dentistry · doi:10.1016/s0300-5712(02)00018-0 · Cited by 104
Graham, D. Y. (2002) · Digestive Diseases and Sciences · doi:10.1023/a:1016495221567 · Cited by 104
Lindsay, R., Pack, S. E., & Li, Z. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1691-5 · Cited by 103
Self-citationHow menopause affects oral health, and what we can do about it
Buencamino, M. C. A., Palomo, L., & Thacker, H. L. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76a.08095 · Cited by 103
Zhu, R., Kan, S.-L., Ning, G., Chen, L., Cao, Z., Jiang, Z., Zhang, X.-L., & Hu, W. F. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4804-2 · Cited by 102
Advances in the management of osteoporosis
Hoong, C. W. S., Saul, D., Khosla, S., & Sfeir, J. G. (2025) · BMJ · doi:10.1136/bmj-2024-081250 · Cited by 101
Langdahl, B. L. (2020) · Bone · doi:10.1016/j.bone.2020.115516 · Cited by 100
Miller, P. D., Epstein, S., Sedarati, F., & Reginster, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253889 · Cited by 100
Self-citationDelmas, P. D., McClung, M. R., Zanchetta, J., Racewicz, A. J., Roux, C., Benhamou, C.-L., Man, Z., Eusebio, R. A., Beary, J. F., Burgio, D. E., et al. (2007) · Bone · doi:10.1016/j.bone.2007.09.001 · Cited by 100
Self-citationSiris, E. S., Bilezikian, J. P., Rubin, M. R., Black, D. M., Bockman, R. S., Bone, H. G., Hochberg, M. C., McClung, M. R., & Schnitzer, T. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030568 · Cited by 99
Chesnut, C. H., Ettinger, M. P., Miller, P. D., Baylink, D. J., Emkey, R., Harris, S. T., Wasnich, R. D., Watts, N. B., Schimmer, R. C., & Recker, R. R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x30752 · Cited by 98
Timing of Subsequent Fractures after an Initial Fracture
van Geel, T. A. C. M., Huntjens, K. M., van den Bergh, J. P., Dinant, G., & Geusens, P. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0023-2 · Cited by 98
Determinants of structure–function relationships among bisphosphonates
Russell, R. G. G. (2007) · Bone · doi:10.1016/j.bone.2007.03.002 · Cited by 98
Alendronate: An Update of its Use in Osteoporosis
Sharpe, M., Noble, S., & Spencer, C. M. (2001) · Drugs · doi:10.2165/00003495-200161070-00010 · Cited by 97
Inoue, T., Fujita, T., Kishimoto, H., Makino, T., Nakamura, T., Nakamura, T., Sato, T. S., & Yamazaki, K. (2008) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-008-0008-8 · Cited by 97
Bone mineral density in people living with HIV: a narrative review of the literature
Kruger, M., & Nell, T. A. (2017) · AIDS Research and Therapy · doi:10.1186/s12981-017-0162-y · Cited by 97
Frost, M. L., Cook, G., Blake, G. M., Marsden, P. K., Benatar, N. A., & Fogelman, I. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2215 · Cited by 96
Boonen, S., Body, J., Boutsen, Y., Devogelaer, J., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1812-1 · Cited by 96
Self-citationHosking, D., Adami, S., Felsenberg, D., Andia, J. C., Välimäki, M., Benhamou, L., Reginster, J.-Y., Yacik, C., Rybak-Feglin, A., Petruschke, R. A., et al. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002009 · Cited by 89
Self-citationCanadian Consensus Conference on Osteoporosis, 2006 Update
Brown, J. P., Fortier, M. P., Frame, H., Lalonde, A. B., Papaioannou, A., Senikas, V., Yuen, C. K., Henneberg, E., Capistran, C., & Oman, J. (2006) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32087-4 · Cited by 95
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.